(NASDAQ: TNXP) Tonix Pharmaceuticals Holding's forecast annual revenue growth rate of 163.24% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 46.39%, and it is also forecast to beat the US market's average forecast revenue growth rate of 16.82%.
Tonix Pharmaceuticals Holding's revenue in 2026 is $17,556,000.On average, 5 Wall Street analysts forecast TNXP's revenue for 2026 to be $424,376,004, with the lowest TNXP revenue forecast at $374,927,640, and the highest TNXP revenue forecast at $472,007,118. On average, 4 Wall Street analysts forecast TNXP's revenue for 2027 to be $1,901,578,151, with the lowest TNXP revenue forecast at $1,584,069,277, and the highest TNXP revenue forecast at $2,217,843,643.
In 2028, TNXP is forecast to generate $3,488,166,075 in revenue, with the lowest revenue forecast at $1,922,301,193 and the highest revenue forecast at $5,121,779,361.